Table 6

Serial changes in lung function 0–4 h postdose forced expiratory volume in one second (l) on days 1 and 28

LS mean change from baseline (SE)Day 1Day 28
PlaceboFF/VITx Diff (95% CI)PlaceboFF/VITx Diff (95% CI)
Predose0.022 (0.0365)0.223 (0.0234)0.201 (0.113 to 0.288)
5 min0.009 (0.0219)0.140 (0.0151)0.131 (0.077 to 0.184)0.038 (0.0370)0.254 (0.0237)0.216 (0.127 to 0.305)
15 min0.038 (0.0282)0.187 (0.0199)0.149 (0.080 to 0.219)0.055 (0.0390)0.279 (0.0249)0.224 (0.130 to 0.317)
30 min0.026 (0.0273)0.205 (0.0193)0.179 (0.112 to 0.246)0.054 (0.0402)0.278 (0.0256)0.225 (0.129 to 0.321)
60 min0.025 (0.0265)0.213 (0.0186)0.188 (0.123 to 0.253)0.071 (0.0382)0.297 (0.0243)0.226 (0.135 to 0.317)
120 min0.028 (0.0285)0.235 (0.0202)0.207 (0.137 to 0.277)0.063 (0.0361)0.285 (0.0231)0.222 (0.135 to 0.308)
240 min−0.003 (0.0358)0.261 (0.0253)0.265 (0.176 to 0.353)0.052 (0.0394)0.278 (0.0252)0.226 (0.132 to 0.321)
  • FF, fluticasone furoate; LS, least squares; Tx, treatment; VI, vilanterol.